Skip to main content

Decoy Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

DCOY$1.11+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders' Equity

Common Stock · Preferred Stock · AdditionalPaid-In · Accumulated · TotalStockholders'
SharesAmountSharesAmountCapitalDeficitEquity
Balance at December 31, 20248,0061——83,435,312(81,923,618)1,511,695
Issuance of equity securities, net3,559———226,170—226,170
Equity-based compensation expense————33,534—33,534
Net loss—————(1,709,533)(1,709,533)
Balance at March 31, 202511,5651——83,695,016(83,633,151)61,866
Issuance of equity securities and other, net253———43,080—43,080
Equity-based compensation expense————23,155—23,155
Net loss—————(957,825)(957,825)
Balance at June 30, 202511,8181——83,761,251(84,590,976)(829,724)
Balance at December 31, 2025531,968531,674—100,331,014(94,442,098)5,888,969
Equity-based compensation expense————213,044—213,044
Net loss—————(2,224,628)(2,224,628)
Balance at March 31, 2026531,968531,674—100,544,058(96,666,726)3,877,385
Issuance of equity securities, net————2,611,144—2,611,144
Equity-based compensation expense————206,177—206,177
Net loss—————(2,373,800)(2,373,800)
Balance at June 30, 2026531,968531,674—103,361,379(99,040,526)4,320,906
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.